Health

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (MF). Selinexor was granted orphan drug designation in MF by the…

thaipr.net

3 พ.ย. 65

AstraZeneca’s long-acting antibody (LAAB) combination granted conditional marketing approval for the treatment of COVID-19 in Thailand

AstraZeneca’s AZD7442 (tixagevimab and cilgavimab), a long-acting antibody combination (LAAB), has been granted conditional marketing approval in Thailand for the treatment of mild to moderate COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg). This approval is in addition to the conditional marketing approval granted to LAAB by […]

thaipr.net

2 พ.ย. 65

NCCN Working with Medlive to Advance High-Quality Cancer Care in China and Worldwide

United States-based National Comprehensive Cancer Network enters strategic cooperation agreement with Chinese medical information website to publish and translate evidence-based expert consensus guidelines for cancer care; now available at nccnchina.org.cn. The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is announcing a new collaboration with Medlive to share NCCN Clinical Practice…

thaipr.net

2 พ.ย. 65

Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

Lo.Li. Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop® promises to be an extremely effective tool in the management of an exceedingly unpredictable disease. Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling a […]

thaipr.net

2 พ.ย. 65

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Marketing authorisation in the European Economic Area anticipated in H1 2023 Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leniolisib has been validated for scientific evaluation under an accelerated assessment by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

thaipr.net

31 ต.ค. 65

Samyang Holdings’ Lafullen Makes Splash in Korean Medical Aesthetics Market

– Successfully demonstrated Lafullen’s safety and efficacy at autumn medical symposiums – Shared treatment protocols and clinical cases to lecturers by specialist – Continued to develop evidence-based marketing to Asian markets Samyang Holdings Biopharmaceuticals Division (CEO: Lee Young-Joon) participated in recent autumn medical symposiums in Korea to raise awareness of Lafullen, an injectable dermal filler. […]

thaipr.net

31 ต.ค. 65

Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa

Cambrex today announced it is investing in a new, 21,000-square-foot research and development facility in Minneapolis, Minnesota, expanding its capacity for small molecule development and manufacturing. Strategically located near the Minneapolis–St. Paul Airport, the new facility will specialize in analytical and chemical development for pharmaceutical drug candidates and will operate as an extension of Cambrex’s […]

thaipr.net

28 ต.ค. 65
1 … 58 59 60 61 62 … 133

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.